Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops product candidates targeting neurological and neuropsychiatric diseases. Its portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have four migraine attacks per month. It is also developing a pipeline of late-stage product candidates across five mechanistic platforms, including CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; MPO inhibition for amyotrophic lateral sclerosis; and Kv7 Ion Channel Activators (Kv7) for focal epilepsy and neuronal hyperexcitability, as well as myostatin inhibition for neuromuscular diseases. The company was incorporated in 2013 and is headquartered in Road Town, British Virgin Islands. As of October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. operates as a subsidiary of Pfizer Inc.